BRPI0517737A - inibidores de quinase - Google Patents

inibidores de quinase

Info

Publication number
BRPI0517737A
BRPI0517737A BRPI0517737-5A BRPI0517737A BRPI0517737A BR PI0517737 A BRPI0517737 A BR PI0517737A BR PI0517737 A BRPI0517737 A BR PI0517737A BR PI0517737 A BRPI0517737 A BR PI0517737A
Authority
BR
Brazil
Prior art keywords
aurora
kinase inhibitors
compositions
compounds
methods
Prior art date
Application number
BRPI0517737-5A
Other languages
English (en)
Inventor
Xiao-Yi Xiao
Dinesh V Patel
Original Assignee
Miikana Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miikana Therapeutics Inc filed Critical Miikana Therapeutics Inc
Publication of BRPI0517737A publication Critical patent/BRPI0517737A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

INIBIDORES DE QUINASE. São descritas inibidores da proteína quinase de Fórmula Ia e Ib, composições que compreendem tais inibidores, e os métodos de uso, dos mesmos. Mais em particular, esses compostos e as composições são inibidores de proteína quinase Aurora-A (Aurora-2) e Aurora-B (Aurora-l) . São também revelados métodos de usar esses compostos e composições para prevenir e tratar doenças associadas com as proteínas quinases, especialmente as doenças associadas com Aurora-A ou Aurora-B, tal como o câncer.
BRPI0517737-5A 2004-11-17 2005-11-17 inibidores de quinase BRPI0517737A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62917604P 2004-11-17 2004-11-17
PCT/US2005/041945 WO2006055831A2 (en) 2004-11-17 2005-11-17 Kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0517737A true BRPI0517737A (pt) 2008-10-21

Family

ID=36407795

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517737-5A BRPI0517737A (pt) 2004-11-17 2005-11-17 inibidores de quinase

Country Status (13)

Country Link
US (1) US8153630B2 (pt)
EP (1) EP1812424A4 (pt)
JP (1) JP2008520713A (pt)
KR (1) KR20070086188A (pt)
CN (1) CN101084214A (pt)
AU (1) AU2005306458B2 (pt)
BR (1) BRPI0517737A (pt)
CA (1) CA2587427A1 (pt)
IL (1) IL183276A0 (pt)
MX (1) MX2007005857A (pt)
NO (1) NO20073024L (pt)
RU (1) RU2007122485A (pt)
WO (1) WO2006055831A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4467616B2 (ja) 2004-05-14 2010-05-26 ミレニアム・ファーマシューティカルズ・インコーポレイテッド Ａｕｒｏｒａキナーゼの阻害により有糸分裂の進行を阻止するための化合物および方法
KR20070086188A (ko) 2004-11-17 2007-08-27 미카나 테라퓨틱스, 인크. 키나제 억제제
BRPI0616630B8 (pt) * 2005-09-30 2021-05-25 Miikana Therapeutics Inc compostos de pirazol substituídos
US7948440B1 (en) 2006-09-30 2011-05-24 LHC2 Inc. Horizontally-polarized omni-directional antenna
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CN101638808B (zh) * 2008-07-31 2012-10-17 复旦大学 筛选加强型抗肿瘤化合物的方法
RU2535032C2 (ru) 2008-12-22 2014-12-10 Милленниум Фармасьютикалз, Инк. Сочетание ингибиторов аврора киназы и анти-cd 20 антител
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
EP2440548A1 (en) 2009-06-10 2012-04-18 Abbott Laboratories 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors
JP2013520424A (ja) 2010-02-19 2013-06-06 ミレニアム ファーマシューティカルズ， インコーポレイテッド ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形
AU2013205306B2 (en) 2012-03-16 2015-09-17 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN105209042B (zh) 2013-03-22 2019-03-08 米伦纽姆医药公司 催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
HRP20220738T1 (hr) 2014-08-11 2022-08-19 Acerta Pharma B.V. Terapijske kombinacije inhibitora btk, inhibitora pd-1 i/ili inhibitora pd-l1
HUE056329T2 (hu) 2014-08-11 2022-02-28 Acerta Pharma Bv BTK-inhibitor és BCL-2-inhibitor terápiás kombinációi
WO2016024232A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
US9592186B2 (en) 2014-09-30 2017-03-14 Avon Products, Inc. Topical compositions and methods for skin lightening
AU2015369690B2 (en) 2014-12-23 2019-01-17 SMA Therapeutics Inc. 3,5-diaminopyrazole kinase inhibitors

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57203072A (en) 1981-06-05 1982-12-13 Sankyo Co Ltd 4-anilinopyrimidine derivative, its preparation, antidepressant comprising it as active ingredient
JPH0665237A (ja) 1992-05-07 1994-03-08 Nissan Chem Ind Ltd 置換ピラゾール誘導体および農園芸用殺菌剤
US5453414A (en) 1993-05-20 1995-09-26 Rohm And Haas Company 2-arylpyrimidines and herbicidal use thereof
ATE163647T1 (de) 1993-08-26 1998-03-15 Ono Pharmaceutical Co 4-aminopyrimidin derivate
WO1996014843A2 (en) 1994-11-10 1996-05-23 Cor Therapeutics, Inc. Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
DE19511562A1 (de) 1995-03-29 1996-10-02 Hoechst Schering Agrevo Gmbh Cyclohexylamino- und alkoxy-Stickstoff-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
NZ506417A (en) 1998-02-17 2003-05-30 Tularik Inc Anti-viral pyrimidine derivatives
KR100860295B1 (ko) 1998-10-08 2008-09-25 아스트라제네카 아베 퀴나졸린 유도체
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
IL145756A0 (en) 2000-02-05 2002-07-25 Vertex Pharma Pyrazole derivatives and pharmaceutical compositions containing the same
CA2400447C (en) 2000-02-17 2008-04-22 Amgen Inc. Kinase inhibitors
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2001079198A1 (en) 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinase
EP1303495B1 (en) 2000-07-24 2010-05-26 Krenitsky Pharmaceuticals, Inc. Substituted 5-alkynyl pyrimidines having neurotrophic activity
JP2004507526A (ja) 2000-08-31 2004-03-11 ファイザー・プロダクツ・インク ピラゾール誘導体及びそのプロテインキナーゼ阻害剤としての使用
KR100876069B1 (ko) * 2000-09-15 2008-12-26 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 약제학적 조성물
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
BR0114020A (pt) 2000-09-20 2003-07-22 Merck Patent Gmbh 4-amino-quinazolinas
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US6716851B2 (en) 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
MXPA03005610A (es) 2000-12-21 2003-10-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
ATE339416T1 (de) 2001-04-13 2006-10-15 Vertex Pharma Inhibitoren von c-jun-n-terminalen-kinasen (jnk) und anderen proteinkinasen
AU2002308748A1 (en) 2001-05-16 2002-11-25 Vertex Pharmaceuticals Incorporated Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
MXPA03010961A (es) 2001-05-31 2004-02-27 Vertex Pharma Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
DE60232510D1 (de) 2001-06-15 2009-07-16 Vertex Pharma 5-(2-aminopyrimidin-4-yl)benzisoxazole als proteinkinasehemmer
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
EP1423380B1 (en) 2001-08-03 2010-12-15 Vertex Pharmaceuticals Incorporated Pyrazole-derived kinase inhibitors and uses thereof
PL211694B1 (pl) 2001-12-24 2012-06-29 Astrazeneca Ab Podstawiona pochodna chinazoliny, jej zastosowania oraz jej kompozycja farmaceutyczna
AU2003225800A1 (en) 2002-03-15 2003-09-29 Hayley Binch Azolylaminoazine as inhibitors of protein kinases
US20040009981A1 (en) 2002-03-15 2004-01-15 David Bebbington Compositions useful as inhibitors of protein kinases
WO2003077921A1 (en) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azinylaminoazoles as inhibitors of protein kinases
ES2289279T3 (es) 2002-03-15 2008-02-01 Vertex Pharmaceuticals Incorporated Composiciones utiles como inhibidores de proteinquinasas.
US6677337B2 (en) 2002-03-19 2004-01-13 The Procter & Gamble Company 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines
US20030207873A1 (en) 2002-04-10 2003-11-06 Edmund Harrington Inhibitors of Src and other protein kinases
WO2003092607A2 (en) 2002-05-01 2003-11-13 Vertex Pharmaceuticals Incorporated Crystal structure of aurora-2 protein and binding pockets thereof
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
US7361665B2 (en) 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
US20040023977A1 (en) 2002-07-15 2004-02-05 Larsen Robert D. Process for making substituted thiazolyl-amino pyrimidinyl
DE60318219T2 (de) 2002-08-24 2009-01-15 Astrazeneca Ab PYRIMIDINDERIVATE ALS MODULATOREN DER AKTIVITuT VON CHEMOKINREZEPTOREN
US7262200B2 (en) 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
EP1635837B1 (en) 2003-06-02 2008-07-16 AstraZeneca AB (3-((quinazolin-4-yl)amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
JP2007510626A (ja) 2003-10-17 2007-04-26 アストラゼネカ アクチボラグ 癌の治療に使用の４−（ピラゾール−３−イルアミノ）ピリミジン誘導体
BRPI0416853A (pt) 2003-11-24 2007-02-13 Hoffmann La Roche pirazolila e imidazolila pirimidinas
AU2004313928A1 (en) 2003-12-02 2005-07-28 Vertex Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors and uses thereof
AR049418A1 (es) 2004-02-27 2006-08-02 Bayer Pharmaceuticals Corp Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
TW200624431A (en) 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7491720B2 (en) 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
KR20070086188A (ko) 2004-11-17 2007-08-27 미카나 테라퓨틱스, 인크. 키나제 억제제
US20060142572A1 (en) 2004-12-14 2006-06-29 Gabriel Martinez-Botella Inhibitors of ERK protein kinase and uses thereof

Also Published As

Publication number Publication date
CA2587427A1 (en) 2006-05-26
AU2005306458A1 (en) 2006-05-26
EP1812424A2 (en) 2007-08-01
WO2006055831A2 (en) 2006-05-26
RU2007122485A (ru) 2008-12-27
US20080200485A1 (en) 2008-08-21
KR20070086188A (ko) 2007-08-27
CN101084214A (zh) 2007-12-05
MX2007005857A (es) 2007-10-10
NO20073024L (no) 2007-07-02
AU2005306458B2 (en) 2011-02-17
IL183276A0 (en) 2007-10-31
WO2006055831A3 (en) 2006-12-07
JP2008520713A (ja) 2008-06-19
US8153630B2 (en) 2012-04-10
EP1812424A4 (en) 2009-07-08

Similar Documents

Publication Publication Date Title
BRPI0517737A (pt) inibidores de quinase
BRPI0616630B8 (pt) compostos de pirazol substituídos
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
TW200801008A (en) Protein kinase inhibitors
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
CL2011001215A1 (es) Compuestos derivados de pirimidina, inhibidores de tirosina quinasa; composiciones farmaceuticas que los comprenden; y su uso en el tratamiento y/o prevencion de cancer, enfermedades inflamatorias y enfermedades autoinmunes.
BRPI0417708A (pt) derivados organofosfóricos dos indazóis e sua utilização como inibidores das proteìnas quinases
MX2010006203A (es) Derivados de pirazol y uso de los mismos como inhibidores de cinasas dependientes de ciclina.
DE602006004844D1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
ATE499364T1 (de) Hemmer der akt aktivität
BRPI0814065B8 (pt) derivados de alcoóis de 1-fenil-2-piridinil alquila como inibidores da fosfodiesterase
DK1791830T3 (da) Diaminotriazol-forbindelser der er nyttige som protein-kinase-inhibitorer
EA201300246A1 (ru) Ингибиторы тирозинкиназы брутона
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
EA201100425A1 (ru) Производные пиколинамида в качестве ингибиторов киназы
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
DE602006007037D1 (de) Pyrrolotriazin-kinasehemmer
BRPI0517921A (pt) métodos para preparar compostos de indazol
GEP20125368B (en) Kinase inhibitors
BRPI0821743B8 (pt) derivados de piridazinona, e seu uso
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.